UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2018~~2019

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-36410

Phibro Animal Health Corporation

(Exact name of registrant as specified in its charter)

	Delaware			13-1840497
	(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
	Glenpointe Centre East, 3rd Floor 300 Frank W. Burr Boulevard, Suite 21 Teaneck, New Jersey (Address of Principal Executive Offices)			07666-6712 (Zip Code)

(201) 329-7300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

	Title of each class			Trading Symbol(s)			Name of each exchange on which registered
	Class A Common Stock, $0.0001 par value per share			PAHC			Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files.) Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions ~~of “large~~of”large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

~~(Do not check if a smaller reporting company)~~

Smaller reporting company

☐

Emerging growth company

☒

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒

As of October ~~30, 2018,~~29, 2019, there were ~~20,209,534~~20,287,574 shares of the registrant’s Class A common stock, par value $0.0001 per share, and 20,166,034 shares of the registrant’s Class B common stock, par value $0.0001 per share, outstanding.

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months						Three Months
For the Periods Ended September 30	2018			2017			2019			2018
	(unaudited) (in thousands, except per share amounts)						(unaudited) (in thousands, except per share amounts)
Net sales		$	200,153		$	193,412		$	189,720		$	200,153
Cost of goods sold			134,348			130,030			132,057			134,348
Gross profit			65,805			63,382			57,663			65,805
Selling, general and administrative expenses			42,952			40,995			47,516			42,952
Operating income			22,853			22,387			10,147			22,853
Interest expense, net			2,783			3,118			3,354			2,783
Foreign currency (gains) losses, net			(2,635)			325			3,221			(2,635)
Income before income taxes			22,705			18,944			3,572			22,705
Provision for income taxes			6,391			3,052			1,057			6,391
Net income		$	16,314		$	15,892		$	2,515		$	16,314
Net income per share
basic		$	0.40		$	0.40
diluted		$	0.40		$	0.39
Basic								$	0.06		$	0.40
Diluted								$	0.06		$	0.40
Weighted average common shares outstanding
basic			40,369			39,944
diluted			40,560			40,293
Dividends per share		$	0.10		$	0.10
Basic									40,454			40,369
Diluted									40,504			40,560

The accompanying notes are an integral part of these consolidated financial statements

TABLE OF CONTENTS

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

As of	September 30, 2018			June 30, 2018			September 30, 2019			June 30, 2019
	(unaudited) (in thousands, except share and per share amounts)						(unaudited) (in thousands, except share and per share amounts)
ASSETS
Cash and cash equivalents		$	25,860		$	29,168		$	54,893		$	57,573
Short-term investments			50,000			50,000			24,000			24,000
Accounts receivable, net			134,815			135,742			145,444			159,022
Inventories, net			185,794			178,170			203,873			198,322
Other current assets			23,324			22,381			27,302			27,245
Total current assets			419,793			415,461			455,512			466,162
Property, plant and equipment, net			130,786			130,108			142,164			140,235
Intangibles, net			51,888			51,978			77,536			47,478
Goodwill			27,348			27,348			52,990			27,348
Other assets			48,660			46,784			67,037			45,448
Total assets		$	678,475		$	671,679		$	795,239		$	726,671
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt		$	12,580		$	12,579		$	14,084		$	12,540
Accounts payable			61,870			59,498			61,372			73,189
Accrued expenses and other current liabilities			54,281			71,144			66,517			68,498
Total current liabilities			128,731			143,221			141,973			154,227
Revolving credit facility			85,000			70,000			168,000			96,000
Long-term debt			226,750			229,802			213,040			217,635
Other liabilities			45,937			43,702			65,532			42,794
Total liabilities			486,418			486,725			588,545			510,656
Commitments and contingencies (Note 8)
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,209,534 and 19,992,204 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively; 30,000,000 Class B shares authorized, 20,166,034 and 20,365,504 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively			4			4
Commitments and contingencies (Note 9)
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,287,574 shares issued and outstanding at September 30, 2019 and June 30, 2019; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at September 30, 2019 and June 30, 2019 and 2018									4			4
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding			—			—			—			—
Paid-in capital			130,649			129,873			133,831			133,266
Retained earnings			145,082			131,560			166,587			168,926
Accumulated other comprehensive income (loss)			(83,678)			(76,483)			(93,728)			(86,181)
Total stockholders’ equity			192,057			184,954			206,694			216,015
Total liabilities and stockholders' equity		$	678,475		$	671,679
Total liabilities and stockholders’ equity								$	795,239		$	726,671

The accompanying notes are an integral part of these consolidated financial statements

TABLE OF CONTENTS

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months						Three Months
For the Periods Ended September 30	2018			2017			2019			2018
	(unaudited) (in thousands)						(unaudited) (in thousands)
OPERATING ACTIVITIES
Net income		$	16,314		$	15,892		$	2,515		$	16,314
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Depreciation and amortization			6,691			6,644			7,781			6,691
Amortization of debt issuance costs and debt discount			221			221			221			221
Stock-based compensation			565			—			565			565
Acquisition-related cost of goods sold			—			249			280			—
Acquisition-related accrued compensation			—			437
Acquisition-related accrued interest			—			253			53			—
Deferred income taxes			(473)			770			(652)			(473)
Foreign currency (gains) losses, net			(2,981)			345			1,660			(2,981)
Other			266			213			116			266
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable, net			(85)			(8,386)			14,065			(85)
Inventories, net			(9,504)			(5,196)			(9,086)			(9,504)
Other current assets			(3,654)			(4,458)			(813)			(3,654)
Other assets			371			332			(1,071)			371
Accounts payable			2,794			3,652			(11,834)			2,794
Accrued expenses and other liabilities			(9,245)			(6,165)			(7,370)			(9,245)
Net cash provided (used) by operating activities			1,280			4,803			(3,570)			1,280
INVESTING ACTIVITIES
Capital expenditures			(6,049)			(4,998)			(7,675)			(6,049)
Business acquisitions			(9,838)			(11,562)			(54,560)			(9,838)
Other, net			(262)			(272)			(296)			(262)
Net cash provided (used) by investing activities			(16,149)			(16,832)			(62,531)			(16,149)
FINANCING ACTIVITIES
Revolving credit facility borrowings			71,000			61,870			119,000			71,000
Revolving credit facility repayments			(56,000)			(41,870)			(47,000)			(56,000)
Payments of long-term debt, capital leases and other			(3,215)			(1,652)
Payments of long-term debt and other									(3,215)			(3,215)
Issuance of acquisition note payable			3,775			—			—			3,775
Proceeds from common shares issued			211			3,486			—			211
Dividends paid			(4,037)			(3,989)			(4,854)			(4,037)
Net cash provided (used) by financing activities			11,734			17,845			63,931			11,734
Effect of exchange rate changes on cash			(173)			198			(510)			(173)
Net increase (decrease) in cash and cash equivalents			(3,308)			6,014			(2,680)			(3,308)
Cash and cash equivalents at beginning of period			29,168			56,083			57,573			29,168
Cash and cash equivalents at end of period		$	25,860		$	62,097		$	54,893		$	25,860

The accompanying notes are an integral part of these consolidated financial statements

TABLE OF CONTENTS

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

	Shares of Common Stock		Common Stock			Preferred Stock			Paid-in Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total
	(unaudited) (in thousands, except share amounts)
As of June 30, 2019		40,453,608		$	4		$	—		$	133,266		$	168,926		$	(86,181)		$	216,015
Comprehensive income (loss)		—			—			—			—			2,515			(7,547)			(5,032)
Exercise of stock options		—			—			—			—			—			—			—
Dividends declared ($0.12 per share)		—			—			—			—			(4,854)			—			(4,854)
Stock-based compensation expense		—			—			—			565			—			—			565
As of September 30, 2019		40,453,608		$	4		$	—		$	133,831		$	166,587		$	(93,728)		$	206,694

	Shares of Common Stock		Common Stock			Preferred Stock			Paid-in Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total
	(unaudited) (in thousands, except share amounts)
As of June 30, 2018		40,357,708		$	4		$	—		$	129,873		$	131,560		$	(76,483)		$	184,954
Adoption of new revenue standard								—			—			1,245			—			1,245
Comprehensive income (loss)		—			—			—			—			16,314			(7,195)			9,119
Exercise of stock options		17,860			—			—			211			—			—			211
Dividends declared ($0.10 per share)		—			—			—			—			(4,037)			—			(4,037)
Stock-based compensation expense		—			—			—			565			—			—			565
As of September 30, 2018		40,375,568		$	4		$	—		$	130,649		$	145,082		$	(83,678)		$	192,057

The accompanying notes are an integral part of these consolidated financial statements

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share amounts)
(unaudited)

Description of Business

Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, cattle, dairy and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries.

The unaudited consolidated financial information for the three months ended September 30, ~~2018~~2019 and ~~2017,~~2018, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, ~~2018~~2019 (the “Annual Report”), filed with the Securities and Exchange Commission on August 27, ~~2018~~2019 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, ~~2018,~~2019, was derived from the audited consolidated financial statements, ~~which include the accounts of Phibro and its consolidated subsidiaries,~~ but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.

The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated infrom the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

Summary of Significant Accounting Policies and New Accounting Standards

Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ~~2014-09,~~2016-02, ~~Revenue from Contracts with Customers~~Leases (Topic ~~606)~~842), effective July 1, ~~2018.~~2019. See “New Accounting Standards” and ~~“Statements of Operations—Additional Information.~~“Note 7—Leases.” As of September 30, ~~2018,~~2019, there have been no other material changes to our significant accounting ~~policies~~policies.

~~Revenue Recognition~~Leases

We determine at the inception of an arrangement whether the arrangement contains a lease. If an arrangement contains a lease, we assess the lease term when the underlying asset is available for use (“lease commencement.”) Individual lease terms reflect the non-cancellable period of the lease, reasonably certain renewal periods and consideration of termination options. We determine the lease classification as either operating or financing at lease commencement, which governs the pattern of expense recognition and presentation in our consolidated financial statements. Our current lease portfolio only includes operating leases.

We recognize ~~revenue from product sales when control~~a right-of-use (“ROU”) asset and a corresponding lease liability at lease commencement for leases with terms exceeding twelve months. Short-term leases with terms of twelve months or less are not recognized on the consolidated balance sheet and lease payments are recognized on a straight-line basis over the term.

The values of the ~~products has transferred~~ROU assets and lease liabilities are calculated based on the present value of the fixed payment obligations over the lease term, using our incremental borrowing rate (“IBR”), determined at lease commencement. The IBR reflects the rate of interest we would expect to pay on a secured basis to borrow an amount equal to the ~~customer, typically when title~~lease payments under similar terms. The IBR incorporates the term and ~~risk of loss transfer to the customer. Certain of our businesses have terms where control~~economic environment of the ~~underlying products transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery.~~

Revenue reflects the total consideration to which we expect to be entitled, in exchange for delivery of products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration primarily use the most-likely amount method. Such estimates are generally based on contractual terms and historical experience, and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of customer incentives. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell.respective lease arrangements.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~Net sales~~We have elected to account for lease and non-lease components together as a single lease component and include ~~shipping~~fixed payment obligations related to such non-lease components in the measurement of ROU assets and ~~handling fees billed~~lease liabilities. Fixed lease payments are recognized on a straight-line basis over the lease term. Variable lease payments can include index-based lease payments, real estate taxes, maintenance costs, utilization charges and other non-lease services paid to ~~customers. The associated costs are considered fulfillment activities, not additional promised services to the customer,~~lessors and are not determinable at lease commencement. Variable lease payments are not included in ~~costs~~the measurement of ~~goods sold~~ROU assets and lease liabilities and are recognized in the ~~consolidated statements of operations when the related revenue is recognized. Net sales exclude value-added and other taxes based on sales.~~period incurred.

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the assumed exercise of stock options and vesting of restricted stock units. All common share equivalents were included in the calculation of diluted net income per share ~~for all~~in the periods ~~presented.~~

Three Months
For the Periods Ended September 30 2018 2017
Net income $ 16,314 $ 15,892
Weighted average number of shares – basic 40,369 39,944
Dilutive effect of stock options and restricted stock units 191 349
Weighted average number of shares – diluted 40,560 40,293
Net income per share
basic $ 0.40 $ 0.40
diluted $ 0.40 $ 0.39

~~Dividends~~

~~We declared and paid a quarterly cash dividend of $0.10 per share, totaling $4,037 during~~included in the ~~three months ended September 30, 2018, to holders of our Class A common stock and Class B common stock. On November 5, 2018, we declared a dividend of $0.12 per share, to be paid December 19, 2018.~~consolidated financial statements.

	Three Months
For the Periods Ended September 30	2019			2018
Net income		$	2,515		$	16,314
Weighted average number of shares – basic			40,454			40,369
Dilutive effect of stock options and restricted stock units			50			191
Weighted average number of shares – diluted			40,504			40,560
Net income per share
basic		$	0.06		$	0.40
diluted		$	0.06		$	0.40

New Accounting Standards

ASU 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, modifies existing disclosure requirements for defined benefit pension and other postretirement plans. This ASU is effective for fiscal years ending after December 15, 2020 and must be applied on a retrospective basis. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.

ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, modifies existing disclosure requirements for fair value measurement. This ASU is effective for fiscal years beginning after December 15, 2019. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.

ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, allows reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects related to adjustments resulting from the United States Tax Cuts and Jobs Act. This ASU is effective for ~~annual reporting periods~~our consolidated financial statements beginning ~~after December 15, 2018. We do not expect~~July 1, 2019. The adoption of this guidance todid not have a material effect on our consolidated financial statements.

ASU ~~2016-15,~~ ~~Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments~~, provides specific guidance for the classification of certain transactions within the statement of cash flows. We adopted this guidance during the three months ended September 30, 2018, and it did not have a material effect on our consolidated financial statements.

~~TABLE OF CONTENTS~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~ASU~~ 2016-02, Leases (Topic 842)~~, supersedes the current lease accounting guidance,~~ requires an entity to recognize assets and liabilities on the balance sheet for both financing and operating leases ~~on the balance sheet~~ and requires additional qualitative and quantitative disclosures regarding leasing arrangements. This ASU and its amendments are effective for annual reporting periods beginning after December 15, 2018. We continue to evaluate the effect of adoption of this guidance on our consolidated financial statements.

~~ASU 2014-09,~~ ~~Revenue from Contracts with Customers (Topic 606)~~, establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. We adopted ASU ~~2014-09~~2016-02 and its amendments effective July 1, ~~2018,~~2019, using ~~the~~a modified retrospective ~~method. Comparative~~transition approach, which does not require modifications to periods prior ~~period amounts were not restated and continue~~ to ~~be reported under~~ the ~~accounting standards in effect for those periods. The adoption of the new revenue standard did not have a material effect on reported net sales or retained earnings.~~

~~The total cumulative effect~~date of initial ~~adoption of the new standard resulted in the following changes~~application. We utilized certain permitted practical expedients intended to ~~our consolidated balance sheet:~~

As of July 1, 2018 Effect of
Adoption Post-adoption
Other current assets $ 2,100 $ 24,481
Other assets 2,325 49,109
Accrued expenses and other current liabilities 343 71,487
Other liabilities 2,837 46,539
Retained earnings $ 1,245 $ 132,805

~~The effect of the adoption of the new revenue standard on our consolidated balance sheet and consolidated statement of operations was:~~

As of September 30, 2018 Effect of
adoption As reported
ASSETS
Other current assets $ 56 $ 23,324
Other assets 56 48,660
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accrued expenses and other current liabilities (80) 54,281
Other liabilities 26 45,937
Retained earnings $ 166 $ 145,082
Three Months
For the Period Ended September 30, 2018 Effect of
adoption As reported
Net sales $ 198 $ 200,153
Provision for income taxes 32 6,391
Net income $ 166 $ 16,314

For changes to our policy as a result of the adoption of ASU 2014-09, see “—Summary of Significant Accounting Policies and New Accounting Standards—Revenue Recognition.” See “Statements of Operations—Additional Information” for our disclosures regarding disaggregated revenue, deferred revenue and customer payment terms.ease

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

transition to the new standard, including carrying forward the original lease classifications without reassessment. We did not use hindsight in our assessment of lease terms as of the effective date. Upon adoption of ASU 2016-02 on July 1, 2019, we recognized initial ROU assets and lease liabilities of $18,576 and $19,368 respectively, on the consolidated balance sheet. The difference in the amounts of the ROU assets and lease liabilities recognized relates to landlord incentives and deferred rent. An adjustment to opening retained earnings was not required, and the recognition of lease expense in the consolidated statements of operations did not change significantly. Refer to “Note 7—Leases” for further information.

Acquisition

In August 2019, we acquired the business and assets of Osprey Biotechnics, Inc. (“Osprey”). Osprey is a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers. The business is included in the Animal Health segment.

We acquired assets used in Osprey’s business, including intellectual property, working capital and property, plant and equipment, for an aggregate cash payment at closing of $54,560, subject to certain customary adjustments. The agreement also includes a future additional payment to be determined based on Osprey’s financial performance for the year ending June 30, 2021. We recorded a $7,553 liability for the estimated future payment. The additional payment will be no less than $4,840 and has no maximum limit.

We accounted for the acquisition as a business combination in accordance with FASB Accounting Standards Codification No. 805, Business Combinations. Pro forma information giving effect to the acquisition has not been provided because the results are not material to the consolidated financial statements. The preliminary fair values of the acquired assets and liabilities as of the acquisition date were:

Working capital, net	$	2,366
Property, plant and equipment		2,005
Definite-lived intangible assets		32,100
Goodwill		25,642
Net assets acquired	$	62,113

We may further refine the determination of certain assets during the measurement period. The definite-lived intangible assets relate to trade names, developed products and customer relationships and will be amortized over estimated useful lives ranging from five to twelve years. The preliminary amount of goodwill has been allocated to our Animal Health segment and is deductible for tax purposes.

Statements of Operations—Additional Information

~~Disaggregated revenue, deferred revenue and customer payment terms~~

We develop, manufacture and market ~~products for~~ a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. The products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold ~~either~~ directly to integrated poultry, swine and cattle integrators orand through commercial animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms.

We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

•

MFAs and Other: ~~The~~ MFAs and other ~~business~~products primarily ~~consists~~consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.

•

Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health.

•

Vaccines: Our vaccines are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We ~~also~~develop, manufacture and ~~distribute~~market licensed and autogenous vaccine products and also market adjuvants to vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.

Mineral Nutrition

The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. ~~Mineral nutrition products are manufactured~~We manufacture and ~~marketed for~~market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle.

Performance Products

The Performance Products business manufactures and markets a number of specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type

	Three Months
For the Periods Ended September 30	2019			2018
Animal Health
MFAs and other		$	75,034		$	87,004
Nutritional specialties			30,433			26,970
Vaccines			16,383			17,215
Total Animal Health		$	121,850		$	131,189
Mineral Nutrition			52,649			54,838
Performance Products			15,221			14,126
Total		$	189,720		$	200,153

Net Sales by Region

	Three Months
For the Periods Ended September 30	2019			2018
United States		$	118,487		$	114,487
Latin America and Canada			36,741			38,883
Europe, Middle East and Africa			23,693			24,836
Asia Pacific			10,799			21,947
Total		$	189,720		$	200,153

1011

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net ~~Sales by Product Type~~

Three Months
For the Periods Ended September 30 2018 2017
Animal Health
MFAs and other $ 87,004 $ 79,603
Nutritional specialties 26,970 30,777
Vaccines 17,215 18,461
Total Animal Health $ 131,189 $ 128,841
Mineral Nutrition 54,838 52,073
Performance Products 14,126 12,498
Total $ 200,153 $ 193,412

~~Net Sales by Region~~

Three Months
For the Periods Ended September 30 2018 2017
United States $ 116,093 $ 113,079
Latin America and Canada 38,258 32,368
Europe, Middle East and Africa 24,858 25,308
Asia Pacific 20,944 22,657
Total $ 200,153 $ 193,412

~~Net~~ sales by region are based on country of destination.

~~Total deferred~~Deferred revenue was ~~$7,414~~$5,276 and ~~$4,530~~$5,464 as of September 30, ~~2018~~2019 and June 30, ~~2018,~~2019, respectively. Accrued expenses and other current liabilities included ~~$778~~$1,002 and ~~$508~~$965 of the total deferred revenue as of September 30, ~~2018~~2019 and June 30, ~~2018,~~2019, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand alone sales prices of the individual products or services.

Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 to 70 days after the revenue is recognized.

Interest Expense and Depreciation and Amortization

	Three Months
For the Periods Ended September 30	2019			2018
Interest expense, net
Term loan		$	2,048		$	2,112
Revolving credit facility			1,431			747
Amortization of debt issuance costs and debt discount			221			221
Acquisition-related accrued interest			53			—
Other			80			163
Interest expense			3,833			3,243
Interest (income)			(479)			(460)
		$	3,354		$	2,783

	Three Months
For the Periods Ended September 30	2019			2018
Depreciation and amortization
Depreciation of property, plant and equipment		$	5,731		$	5,188
Amortization of intangible assets			2,038			1,491
Amortization of other assets			12			12
		$	7,781		$	6,691

Balance Sheets—Additional Information

As of	September 30, 2019			June 30, 2019
Inventories
Raw materials		$	71,737		$	64,441
Work-in-process			8,934			10,699
Finished goods			123,202			123,182
		$	203,873		$	198,322

As of	September 30, 2019			June 30, 2019
Goodwill roll-forward
Balance at beginning of period		$	27,348		$	27,348
Osprey acquisition			25,642			—
Balance at end of period		$	52,990		$	27,348

1112

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~Interest expense and Depreciation and amortization~~

Three Months
For the Periods Ended September 30 2018 2017
Interest expense, net
Term loan $ 2,112 $ 2,033
Revolving credit facility 747 681
Amortization of debt issuance costs and debt discount 221 221
Acquisition-related accrued interest — 253
Other 163 239
Interest expense 3,243 3,427
Interest (income) (460) (309)
$ 2,783 $ 3,118
Depreciation and amortization
Depreciation of property, plant and equipment $ 5,188 $ 5,183
Amortization of intangible assets 1,491 1,449
Amortization of other assets 12 12
$ 6,691 $ 6,644

~~Balance Sheets—Additional Information~~

As of
September 30,
2018

June 30,
2018

Inventories
Raw materials $ 79,384 $ 62,373
Work-in-process 14,707 14,731
Finished goods 91,703 101,066
$ 185,794 $ 178,170

As of	September 30, 2019			June 30, 2019
Other assets
Equity method investments		$	4,374		$	4,196
Insurance investments			5,521			5,431
Deferred financing fees			1,404			1,531
Deferred income taxes			17,357			16,770
ROU operating lease assets			20,830			—
Deposits			6,534			7,024
Indemnification asset			3,000			3,000
Other			8,017			7,496
		$	67,037		$	45,448

We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a ~~$3,491~~$3,446 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.

As of	September 30, 2018			June 30, 2018			September 30, 2019			June 30, 2019
Accrued expenses and other current liabilities
Employee related		$	19,852		$	27,333		$	25,999		$	28,298
Current operating lease liabilities									6,267			—
Commissions and rebates			5,784			7,341			7,366			8,397
Insurance-related			1,236			1,168			1,274			1,279
Professional fees			4,331			4,350			3,993			5,212
Income and other taxes			4,406			3,610			3,655			6,067
Acquisition-related consideration			3,877			12,845
Fair value of derivatives			60			—
Restructuring costs									2,655			3,590
Other			14,735			14,497			15,308			15,655
		$	54,281		$	71,144		$	66,517		$	68,498

During the ~~quarter~~three months ended June 30, 2019, we initiated business restructuring activities related to productivity and cost saving initiatives in the Animal Health segment. We recorded pre-tax charges of $6,281 for these activities, including $3,500 related to the termination of a contract manufacturing agreement and $2,781 for employee separation charges. As of June 30, 2019, $691 had been paid.

During the three months ended September 30, ~~2018,~~2019, we ~~accelerated~~recorded an additional $425 and paid $1,360 related to employee separation charges. Business restructuring activities during the ~~closing date~~three months ended September 30, 2019, are summarized in the below table:

Liability balance at June 30, 2019	$	5,590
Charges		425
Payments		(1,360)
Liability balance at September 30, 2019	$	4,655

The charges are included in selling, general and ~~completed~~administrative expenses in our consolidated statements of operations. As of September 30, 2019, $2,655 was included in accrued expenses and other current liabilities and $2,000 was included in other liabilities. We expect to record an additional charge for employee separation costs of an estimated $500 and complete the purchase of intellectual property and certain other assets comprising the MJ Biologics, Inc. (“MJB”) business relating to animal vaccines. The Company and MJB had originally agreed in January 2015 to the purchase business combination, with a contemplated final closing date in January 2021. The final amount due, net of previously paid amounts, was $12,775, including $9,000 paid in July 2018 and a $3,775 acquisition note payable in Januaryadditional separation actions by December 31, 2019.

1213

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of
September 30,
2018

June 30,
2018

Accumulated other comprehensive income (loss)
Derivative instruments $ 5,527 $ 4,986
Foreign currency translation adjustment (74,780) (67,098)
Unrecognized net pension gains (losses) (18,105) (18,213)
(Provision) benefit for income taxes on derivative instruments (1,376) (1,241)
(Provision) benefit for income taxes on long-term intercompany investments 8,166 8,166
(Provision) benefit for income taxes on pension gains (losses) (3,110) (3,083)
$ (83,678) $ (76,483)

As of	September 30, 2019			June 30, 2019
Other liabilities
U.S. pension plan		$	3,545		$	3,934
International retirement plans			5,139			5,133
Supplemental retirement benefits, deferred compensation and other			7,713			7,605
Long term and deferred income taxes			9,022			8,978
Acquisition-related consideration			7,603			—
Long-term operating lease liabilities			15,546			—
Restructuring costs			2,000			2,000
Other long term liabilities			14,964			15,144
		$	65,532		$	42,794

As of	September 30, 2019			June 30, 2019
Accumulated other comprehensive income (loss)
Derivative instruments		$	(1,678)		$	(594)
Foreign currency translation adjustment			(78,048)			(71,225)
Unrecognized net pension gains (losses)			(19,930)			(20,050)
(Provision) benefit for income taxes on derivative instruments			418			148
(Provision) benefit for incomes taxes on long-term intercompany investments			8,166			8,166
(Provision) benefit for income taxes on pension gains (losses)			(2,656)			(2,626)
		$	(93,728)		$	(86,181)

5.6.

Debt

Term Loans and Revolving Credit Facilities

Pursuant to a credit agreement (the “Credit Agreement”), we have a revolving credit facility (the “Revolver”), where we can borrow up to $250,000, subject to the terms of the agreement, and a term A loan with an aggregate initial principal amount of $250,000 (the “Term A Loan,” and together with the Revolver, the “Credit Facilities”). The Credit Facilities have applicable margins equal to 2.00%, 1.75% or 1.50%, in the case of LIBOR and Eurodollar rate loans and 1.00%, 0.75% or 0.50%, in the case of base rate loans; the applicable margins are based on the First Lien Net Leverage Ratio, as defined in the Credit Agreement. The LIBOR rate is subject to a floor of 0.00%. The Credit Facilities mature on June 29, 2022.

The Credit Facilities require, among other things, the maintenance of (i) a maximum First Lien Net Leverage Ratio and (ii) a minimum consolidated interest coverage ratio, each calculated on a trailing four quarter basis, and contain an acceleration clause should an event of default (as defined in the ~~agreement governing the~~ Credit ~~Facilities)~~Agreement) occur. As of September 30, ~~2018,~~2019, we were in compliance with the ~~covenants of the Credit Facilities.~~financial covenants.

As of September 30, ~~2018,~~2019, we had ~~$85,000~~$168,000 in borrowings under the Revolver and had outstanding letters of credit of ~~$4,191,~~$3,009, leaving ~~$160,809~~$78,991 available for borrowings and letters of credit under the Revolver. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one ~~year or less.~~year.

As of September 30, ~~2018,~~2019, the interest rates for the Revolver and the Term A Loan were ~~3.76%~~3.53% and ~~3.49%~~3.42%, respectively. The weighted-average interest rates for the outstanding revolving credit facilities were ~~3.68%~~3.70% and ~~2.98%~~3.68% for the three months ended September ~~30,~~31, 2019 and 2018, ~~and 2017,~~ respectively. The weighted-average interest rates for the term loans were ~~3.43%~~3.48% and ~~3.22%~~3.43% for the three months ended September 30, 2019 and 2018, ~~and 2017,~~ respectively.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

In July 2017, we entered into an interest rate swap agreement on ~~$150 million~~$150,000 of notional principal that effectively converts the floating LIBOR ~~or base rate~~ portion of our interest obligation on that amount of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. ~~The~~We designated the interest rate swap ~~has been designated~~ as a highly effective cash flow hedge. For additional details, see “—Derivatives.”

Long-Term Debt

As of	September 30, 2019			June 30, 2019
Term A Loan due June 2022		$	228,125		$	231,250
Other			21			40
			228,146			231,290
Unamortized debt issuance costs and debt discount			(1,022)			(1,115)
			227,124			230,175
Less: current maturities			(14,084)			(12,540)
		$	213,040		$	217,635

Leases

Our lease portfolio consists of real estate, vehicles and equipment ROU assets, classified as operating leases. As of September 30, 2019, the remaining non-cancelable lease terms, inclusive of renewal options reasonably certain of exercise, range from one to 20 years.

The following table summarizes the ROU assets and the related lease liabilities recorded on the consolidated balance sheet:

As of	September 30, 2019			Balance Sheet Classification
Assets:
Operating lease ROU assets		$	20,830	Other Assets
Liabilities:
Current portion			6,267	Accrued expenses and other current liabilities
Non-current portion			15,546	Other liabilities
Total operating lease liabilities		$	21,813

The following table summarizes the composition of net lease cost:

	Three months
For the Period Ended September 30	2019
Operating lease expense		$	1,851
Variable lease expense			324
Short-term lease expense			203
Total lease cost		$	2,378

The following tables include other supplemental information:

	Three months
For the Period Ended September 30	2019
Operating cash flows used for ROU operating leases		$	1,677
Right of use assets obtained in exchange for new operating lease liabilities (non-cash)		$	3,790

1315

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

	As of
	September 30, 2019
Weighted average remaining lease term (in years) – ROU operating leases		6.36
Weighted average discount rate – ROU operating leases		4.13%

~~Long-Term Debt~~At September 30, 2019, maturities of future lease liabilities are:

As of
September 30,
2018

June 30,
2018

Term A Loan due June 2022 $ 240,625 $ 243,750
Capitalized lease obligations 99 118
240,724 243,868
Unamortized debt issuance costs and debt discount (1,394) (1,487)
239,330 242,381
Less: current maturities (12,580) (12,579)
$ 226,750 $ 229,802

For the Years Ending June 30
2020	$	5,450
2021		5,856
2022		4,382
2023		2,258
2024		1,786
2025 and thereafter		5,473
Total lease payments		25,205
Less: interest		3,392
Total operating lease liabilities	$	21,813

6.There were no significant future payment obligations related to executed lease agreements for which the related lease had not yet commenced as of September 30, 2019. Our lease agreements do not contain any material restrictive covenants or residual value guarantee provisions.

Future minimum lease payments for operating leases accounted for under ASC 840, “Leases,” with remaining non-cancelable terms in excess of one year at June 30, 2019 were:

For the Years Ending June 30
2020	$	5,815
2021		4,160
2022		3,191
2023		1,445
2024		865
Thereafter		765
Total minimum lease payments	$	16,241

Related Party Transactions

Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to us as employees or consultants and received aggregate compensation and benefits of approximately ~~$783~~$451 and ~~$720~~$783 during the three months ended September 30, ~~2018~~2019 and ~~2017,~~2018, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

~~Income Taxes~~

In December 2017, the United States government enacted comprehensive income tax legislation (the “Tax Act”). The Tax Act makes broad and complex changes to United States income tax law and includes numerous elements that affect the Company, including a reduced federal corporate income tax rate from 35% to 21%, creating a territorial tax system that includes a one-time mandatory transition tax on previously deferred foreign earnings and changes to business-related exclusions, deductions and credits. The Tax Act also has consequences related to our international operations.

We have substantially completed our analysis and accounting for the Tax Act. However, the ultimate financial statement effects of the Tax Act could differ from the amounts we have recognized to date, due to additional information that becomes available, changes in regulations or interpretations, legislative action to address questions around the Tax Act or changes in accounting standards for income taxes or related interpretations. As such, the amounts we have recorded are provisional and we could adjust such amounts in the three months ended December 31, 2018, if additional new information so requires.

8.9.

Commitments and Contingencies

Environmental

Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities.

~~TABLE OF CONTENTS~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.

The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of Phibro-Tech’s Santa Fe Springs, California facility. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that any groundwater contamination at its site is localized and due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA and RCRA in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA’s investigation, the preliminary stage of the ongoing litigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.

Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be

~~TABLE OF CONTENTS~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Claims and Litigation

PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, ~~our insurance policies will cover~~ such ~~claims.~~claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

9.10.

Derivatives

We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are ~~recorded as an asset or liability with a corresponding amount~~ recorded in accumulated other comprehensive income (loss).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “—Fair Value Measurements.”

We entered into an interest rate swap agreement on $150,000 of notional principal that effectively converts the floating LIBOR ~~or base rate~~ portion of our interest obligation on that amount of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. The forecasted transactions are probable of occurring, and the interest rate swap has been designated as a highly effective cash flow hedge.

We entered into foreign currency option contracts to hedge cash flows related to monthly inventory purchases. The individual option contracts mature monthly through June ~~2020.~~2021. The forecasted inventory purchases are probable of occurring and the individual option contracts were designated as highly effective cash flow hedges.

The following table ~~summarizes~~details the Company’s outstanding derivatives that are designated and effective as cash flow hedges as of September 30, ~~2018:~~2019:

Instrument	Hedge	Notional Amount at September 30, 2018	Consolidated Balance Sheet		Fair value as of						Hedge	Notional Amount at September 30, 2019	Consolidated Balance Sheet	Asset (Liability) fair value as of
					September 30, 2018			June 30, 2018						September 30, 2019			June 30, 2019
Options	Brazilian Real calls	R$94,500		(1)		$	496		$	71	Brazilian Real calls	R$90,000	(1)		$	390		$	413
Options	Brazilian Real puts	R$94,500		(1)		$	(556)		$	—	Brazilian Real puts	R$90,000	(1)		$	(370)		$	(30)
Swap	Interest rate swap	$150,000	Other assets			$	5,728		$	5,078	Interest rate swap	$150,000	Other assets / (Other liabilities)		$	(1,698)		$	(977)

(1)

We record the net fair values of our outstanding foreign currency option contracts within the respective balance sheet line item based on the net financial position and maturity date of the individual contracts as of the balance sheet date. AsOther current assets as of September 30, ~~2018, the~~2019 and June 30, 2019, included net fair ~~value~~values of ~~$60 was included in accrued expenses~~$20 and ~~other current liabilities. As of June 30, 2018, the net fair value of $71 was included in other current assets.~~$383, respectively.

~~TABLE OF CONTENTS~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

For the Three Months Ended September 30	For the Three Months Ended September 30																					For the Three Months Ended September 30
Instrument		Hedge	Gain (Loss) recorded in OCI						Gain (Loss) recognized in consolidated statements of operations							Consolidated Statement of Operations Line Item Total
																								Gain (Loss) recorded in OCI						Gain (Loss) recognized in consolidated statements of operations							Consolidated Statement of Operations Line Item Total
Instrument		Hedge	2018			2017			Consolidated Statement of Operations	2018			2017			2018			2017				Hedge	2019			2018			Consolidated Statement of Operations	2019			2018			2019			2018
				$	(109)		$	(905)	Cost of goods sold		$	1,084		$	186		$	134,348		$	130,030		Brazilian Real calls		$	(363)		$	(109)	Cost of goods sold		$	(45)		$	1084		$	132,057		$	134,348
Swap		Interest rate swap		$	650		$	283	Interest expense, net		$	—		$	—		$	2,783		$	3,118		Interest rate swap		$	(721)		$	650	Interest expense, net		$	—		$	—		$	3,354		$	2,783

We recognize gains (losses) related to these foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold. Realized net gains of $1,084 related to matured contracts were recorded as a component of inventory as of June 30, 2018 and were recognized as an offset to costs of goods sold during the three months ended September 30, 2018.

~~10.~~11.

Fair Value Measurements

Short-term investments

As of September 30, ~~2018,~~2019, our short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value.

Current Assets and Liabilities

We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.

Contingent Consideration on Acquisitions

We determine the fair value of contingent consideration on acquisitions based on contractual terms, our current forecast of performance factors related to the acquired business and an applicable discount rate.

Letters of Credit

We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The carrying values of these letters of credit are considered to be representative of their fair values because of the nature of the instruments.

Debt

We record debt, including term loans and revolver balances, at book value in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments.

Derivatives

We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation ~~rates,~~rates.

Non-financial assets

Our non-financial assets, which primarily consist of goodwill, other intangible assets, property and ~~interest rate curves.~~

~~Fair Value of Assets (Liabilities)~~

As of September 30, 2018 June 30, 2018
Level 1 Level 2 Level 1 Level 2
Short-term investments $ 50,000 $ — $ 50,000 $ —
Derivatives asset (liability) $ — $ (60) $ — $ 71
Interest rate swap $ — $ 5,728 $ — $ 5,078

~~There were no Level 3~~equipment, and lease-related ROU assets, are not required to be measured at fair value ~~measurements~~on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. We assess the carrying values of non-financial assets for ~~the periods presented.~~impairment on a periodic basis or whenever events or changes in circumstances indicate an asset may not be fully recoverable.

1719

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~11.~~Fair Value of Assets (Liabilities)

As of	September 30, 2019									June 30, 2019
	Level 1			Level 2			Level 3			Level 1			Level 2			Level 3
Short-term investments		$	24,000		$	—		$	—		$	24,000		$	—		$	—
Derivatives asset (liability)		$	—		$	20		$	—		$	—		$	383		$	—
Interest rate swap (liability)		$	—		$	(1,698)		$	—		$	—		$	(977)		$	—
Contingent consideration on acquisitions		$	—		$	—		$	(7,603)		$	—		$	—		$	—

During the three months ended September 30, 2019, we recorded $7,603 of contingent consideration associated with the Osprey acquisition, inclusive of accrued interest.

12.

Business Segments

We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development. ~~Corporate assets include cash and cash equivalents, certain debt issue costs, income tax related assets and certain other assets.~~

We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (e) certain items that we consider to be unusual, non-operational or non-recurring.

The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.

	Three Months						Three Months
For the Periods Ended September 30	2018			2017			2019			2018
Net sales
Animal Health		$	131,189		$	128,841		$	121,850		$	131,189
Mineral Nutrition			54,838			52,073			52,649			54,838
Performance Products			14,126			12,498			15,221			14,126
Total segments		$	200,153		$	193,412		$	189,720		$	200,153
Depreciation and amortization
Animal Health		$	5,356		$	5,254		$	6,384		$	5,356
Mineral Nutrition			597			585			613			597
Performance Products			273			246			377			273
Total segments		$	6,226		$	6,085		$	7,374		$	6,226
Adjusted EBITDA
Animal Health		$	35,716		$	33,742		$	25,061		$	35,716
Mineral Nutrition			2,563			3,716			3,475			2,563
Performance Products			716			248			852			716
Total segments		$	38,995		$	37,706		$	29,388		$	38,995

1820

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Three Months
For the Periods Ended September 30 2018 2017
Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes $ 22,705 $ 18,944
Interest expense, net 2,783 3,118
Depreciation and amortization – Total segments 6,226 6,085
Depreciation and amortization – Corporate 465 559
Corporate costs 8,886 7,589
Stock-based compensation 565 —
Acquisition-related cost of goods sold — 249
Acquisition-related accrued compensation — 437
Acquisition-related transaction costs — 400
Foreign currency (gains) losses, net (2,635) 325
Adjusted EBITDA – Total segments $ 38,995 $ 37,706

As of
September 30,
2018

June 30,
2018

Identifiable assets
Animal Health $ 461,119 $ 455,704
Mineral Nutrition 73,895 69,779
Performance Products 29,048 24,040
Total segments 564,062 549,523
Corporate 114,413 122,156
Total $ 678,475 $ 671,679

	Three Months
For the Periods Ended September 30	2019			2018
Reconciliation of income before income taxes to Adjusted EBITDA
Income before income taxes		$	3,572		$	22,705
Interest expense, net			3,354			2,783
Depreciation and amortization – Total segments			7,374			6,226
Depreciation and amortization – Corporate			407			465
Corporate costs			9,728			8,886
Restructure costs			425			—
Stock-based compensation			565			565
Acquisition-related cost of goods sold			280			—
Acquisition-related transaction costs			462			—
Foreign currency (gains) losses, net			3,221			(2,635)
Adjusted EBITDA – Total segments		$	29,388		$	38,995

As of	September 30, 2019			June 30, 2019
Identifiable assets
Animal Health		$	572,933		$	508,864
Mineral Nutrition			71,551			67,662
Performance Products			33,323			32,886
Total segments			677,807			609,412
Corporate			117,432			117,259
Total		$	795,239		$	726,671

The Animal Health segment includes all goodwill of the Company. The Animal Health segment includes advances to and investment in an equity method investee of ~~$3,491~~$3,446 and ~~$3,432~~$3,287 as of September 30, ~~2018~~2019 and June 30, ~~2018,~~2019, respectively. The Performance Products segment includes an investment in an equity method investee of ~~$528~~$852 and ~~$437~~$759 as of September 30, ~~2018~~2019 and June 30, ~~2018,~~2019, respectively. Corporate assets include cash and cash equivalents, short-term investments, ~~certain~~ debt issuance costs, income tax related assets and certain other assets.

1921

TABLE OF CONTENTS

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” and “Forward-Looking Statements.”

Overview of our business

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. We develop, manufacture and market ~~products for~~ a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and performance and contribute to balanced mineral nutrition. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

TABLE OF CONTENTS

Analysis of the consolidated statements of operations

Summary Results of Operations

	Three Months										Three Months
For the Periods Ended September 30	2018			2017			Change				2019			2018			Change
	(in thousands, except per share amounts and percentages)										(in thousands, except per share amounts and percentages)
Net sales		$	200,153		$	193,412		$	6,741	3%		$	189,720		$	200,153		$	(10,433)	(5)%
Gross profit			65,805			63,382			2,423	4%			57,663			65,805			(8,142)	(12)%
Selling, general and administrative expenses			42,952			40,995			1,957	5%			47,516			42,952			4,564	11%
Operating income			22,853			22,387			466	2%	��		10,147			22,853			(12,706)	(56)%
Interest expense, net			2,783			3,118			(335)	(11)%			3,354			2,783			571	21%
Foreign currency (gains) losses, net			(2,635)			325			(2,960)	*			3,221			(2,635)			5,856	*
Income before income taxes			22,705			18,944			3,761	20%			3,572			22,705			(19,133)	(84)%
Provision for income taxes			6,391			3,052			3,339	109%			1,057			6,391			(5,334)	(83)%
Net income		$	16,314		$	15,892		$	422	3%		$	2,515		$	16,314		$	(13,799)	(85)%
Net income per share
basic		$	0.40		$	0.40			—			$	0.06		$	0.40		$	(0.34)
diluted		$	0.40		$	0.39		$	0.01			$	0.06		$	0.40		$	(0.34)
Weighted average number of shares outstanding
basic			40,369			39,944							40,454			40,369
diluted			40,560			40,293							40,504			40,560
Ratio to net sales
Gross profit			32.9%			32.8%							30.4%			32.9%
Selling, general and administrative expenses			21.5%			21.2%							25.0%			21.5%
Operating income			11.4%			11.6%							5.3%			11.4%
Income before income taxes			11.3%			9.8%							1.9%			11.3%
Net income			8.2%			8.2%							1.3%			8.2%
Effective tax rate			28.1%			16.1%							29.6%			28.1%

Certain amounts and percentages may reflect rounding adjustments.

Calculation not meaningful

2023

TABLE OF CONTENTS

Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA

We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures.”

Segment net sales and Adjusted EBITDA:

	Three Months										Three Months
For the Periods Ended September 30	2018			2017			Change				2019			2018			Change
	(in thousands, except percentages)										(in thousands, except percentages)
Net sales
MFAs and other		$	87,004		$	79,603		$	7,401	9%		$	75,034		$	87,004		$	(11,970)	(14)%
Nutritional specialties			26,970			30,777			(3,807)	(12)%			30,433			26,970			3,463	13%
Vaccines			17,215			18,461			(1,246)	(7)%			16,383			17,215			(832)	(5)%
Animal Health			131,189			128,841			2,348	2%			121,850			131,189			(9,339)	(7)%
Mineral Nutrition			54,838			52,073			2,765	5%			52,649			54,838			(2,189)	(4)%
Performance Products			14,126			12,498			1,628	13%			15,221			14,126			1,095	8%
Total		$	200,153		$	193,412		$	6,741	3%		$	189,720		$	200,153		$	(10,433)	(5)%
Adjusted EBITDA
Animal Health		$	35,716		$	33,742		$	1,974	6%		$	25,061		$	35,716		$	(10,655)	(30)%
Mineral Nutrition			2,563			3,716			(1,153)	(31)%			3,475			2,563			912	36%
Performance Products			716			248			468	189%			852			716			136	19%
Corporate			(8,886)			(7,589)			(1,297)	*			(9,728)			(8,886)			(842)	*
Total		$	30,109		$	30,117		$	(8)	(0)%		$	19,660		$	30,109		$	(10,449)	(35)%
Adjusted EBITDA ratio to segment net sales
Animal Health			27.2%			26.2%							20.6%			27.2%
Mineral Nutrition			4.7%			7.1%							6.6%			4.7%
Performance Products			5.1%			2.0%							5.6%			5.1%
Corporate(1)			(4.4)%			(3.9)%							(5.1)%			(4.4)%
Total(1)			15.0%			15.6%							10.4%			15.0%

(1)

reflects ratio to total net sales

2124

TABLE OF CONTENTS

The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

	Three Months										Three Months
For the Periods Ended September 30	2018			2017			Change				2019			2018			Change
	(in thousands, except percentages)										(in thousands, except percentages)
Net income		$	16,314		$	15,892		$	422	3%		$	2,515		$	16,314		$	(13,799)	(85)%
Interest expense, net			2,783			3,118			(335)	(11)%			3,354			2,783			571	21%
Provision (benefit) for income taxes			6,391			3,052			3,339	109%
Provision for income taxes													1,057			6,391			(5,334)	(83)%
Depreciation and amortization			6,691			6,644			47	1%			7,781			6,691			1,090	16%
EBITDA			32,179			28,706			3,473	12%			14,707			32,179			(17,472)	(54)%
Restructuring costs													425			—			425	*
Stock-based compensation			565			—			565	*			565			565			—	0%
Acquisition-related cost of goods sold			—			249			(249)	*			280			—			280	*
Acquisition-related accrued compensation			—			437			(437)	*
Acquisition-related transaction costs			—			400			(400)	*			462			—			462	*
Foreign currency (gains) losses, net			(2,635)			325			(2,960)	*			3,221			(2,635)			5,856	*
Adjusted EBITDA		$	30,109		$	30,117		$	(8)	(0)%		$	19,660		$	30,109		$	(10,449)	(35)%

Certain amounts and percentages may reflect rounding adjustments.

Calculation not meaningful

Comparison of three months ended September 30, ~~2018~~2019 and ~~2017~~2018

Net sales

Net sales of ~~$200.2~~$189.7 million for the three months ended September 30, ~~2018, increased $6.7~~2019, decreased $10.4 million, or 3%5%, as compared to the three months ended September 30, ~~2017.~~2018. Animal Health and Mineral Nutrition declined $9.3 million and $2.2 million, respectively. Performance Products grew ~~$2.3 million, $2.8 million and $1.6 million, respectively.~~$1.1 million.

Animal Health

Net sales of ~~$131.2~~$121.9 million for the three months ended September 30, ~~2018, grew $2.3~~2019, declined $9.3 million, or 2%7%. Net sales of MFAs and other ~~increased $7.4~~declined $12.0 million, or 9%14%, ~~driven by continued international volume growth, particularly in the cattle sector. Reduced selling prices in certain countries~~primarily due to ~~unfavorable exchange rate movements partially offset~~reduced demand related to the ~~international volume growth.~~effect of African Swine Fever in China. Net sales of ~~domestic~~ MFAs and other also ~~contributed~~declined in other international regions due to ~~the growth.~~customer order patterns. Net sales of nutritional specialty products ~~declined by $3.8~~grew $3.5 million, or ~~12%~~13%, ~~primarily~~ due to volume ~~declines from~~growth in poultry and dairy products. The recent Osprey acquisition accounted for approximately one-half of the ~~continued negative dairy industry conditions, while~~nutritional specialty sales ~~to the poultry sector were approximately even with the prior year.~~growth. Net sales of vaccines declined ~~$1.2~~$0.8 million, or 7%5%. The loss of a domestic distribution arrangement in October 2018 offset volume growth in most regions. Net sales of vaccines would have increased approximately 5%, ~~due to turbulent economic conditions in certain international countries and~~excluding the ~~timing~~loss of ~~certain vaccine orders in~~ the ~~prior year.~~distribution arrangement.

Mineral Nutrition

Net sales of ~~$54.8~~$52.6 million ~~increased $2.8 million, or 5%,~~ for the three months ended September 30, ~~2018. Higher~~2019, decreased $2.2 million, or 4%. Lower average selling prices, ~~related to increased commodity prices were the primary driver of the increased revenue. Our selling prices of mineral nutrition products generally move in direct correlation~~correlated with the movement of underlying ~~commodity costs. Net sales also declined in part due to reduced volumes due to the competitive nature of the business.~~raw material costs, offset increased volumes.

Performance Products

Net sales of ~~$14.1~~$15.2 million ~~increased $1.6 million, or 13%,~~ for the three months ended September 30, ~~2018, due to higher unit~~2019, increased $1.1 million, or 8%, driven by increased volumes of ~~copper-based products coupled with higher average selling prices~~personal care ingredients, partially offset by lower volume of ~~certain industrial chemical~~copper-based products.

2225

TABLE OF CONTENTS

Gross profit

Gross profit of ~~$65.8~~$57.7 million for the three months ended September 30, ~~2018, increased $2.4~~2019, decreased $8.1 million, or 4%12%, as compared to the three months ended September 30, ~~2017.~~2018. Gross profit ~~increased~~decreased to ~~32.9%~~30.4% of net sales for the three months ended September 30, ~~2018,~~2019, as compared to ~~32.8%~~32.9% for the three months ended September 30, ~~2017.~~ 2018. The three months ended September 30, 2019, included $0.3 million of acquisition-related cost of goods sold.

Animal Health gross profit ~~increased $3.0~~decreased $8.5 million due to volume ~~growth~~declines and ~~favorable unit costs and~~unfavorable product mix in MFAs and other and vaccines, partially offset by volume ~~declines of~~growth in nutritional specialty products. Mineral Nutrition gross profit ~~decreased $1.2~~increased $0.9 million, ~~primarily due to unfavorable~~as favorable raw material costs and product mix ~~and constrained pricing~~offset the decline in ~~a competitive environment.~~average selling prices. Performance Products gross profit decreased $0.2 million, as increased ~~$0.4 million, primarily due to increased~~unit volumes ~~and favorable~~were more than offset by unfavorable manufacturing costs. ~~Gross profit increased $0.2 million due to acquisition-related cost of goods sold included in the three months ended September 30, 2017.~~

Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of ~~$43.0~~$47.5 million for the three months ended September 30, ~~2018,~~2019, increased ~~$2.0~~$4.6 million, or 5%11%, as compared to the three months ended September 30, ~~2017.~~2018. SG&A for the three months ended September 30, 2019, included $0.4 million of restructuring costs, $0.6 million of stock-based compensation and $0.5 million of acquisition-related transaction costs. SG&A for the three months ended September 30, 2018, included $0.6 million of stock-based compensation. ~~SG&A for the three months ended September 30, 2017, included $0.4 million in acquisition-related transaction costs and $0.4 million in acquisition-related compensation costs.~~ Excluding the effects of these costs, SG&A increased ~~$2.3~~$3.7 million, or 6%9%.

Animal Health SG&A increased ~~$1.1~~$3.1 million, ~~driven by sales force expansion and~~including increased investments in ~~marketing~~product development and ~~product development.~~the effect of the Osprey acquisition. Mineral Nutrition SG&A was comparable to the prior year and Performance Products ~~SG&A costs were even with the prior year.~~decreased $0.2 million. Corporate ~~costs~~expenses increased ~~$1.2~~$0.8 million due to increased ~~business development expenses~~costs of strategic initiatives and ~~higher professional fees.~~public company costs. The restructuring costs, stock-based compensation ~~acquisition-related transaction costs~~ and acquisition-related ~~compensation~~ costs resulted in a ~~$0.3~~net $0.9 million ~~net decrease in~~increase to SG~~&A compared to the prior year.~~&A.

Interest expense, net

Interest expense, net of ~~$2.8~~$3.4 million for the three months ended September 30, ~~2018, decreased $0.3~~2019, increased $0.6 million, or ~~11%~~21%, as compared to the three months ended September 30, ~~2017.~~2018. The increase in interest expense was primarily driven by the increase in outstanding borrowings on the Revolver. Interest ~~expense decreased $0.2 million compared~~income from short-term investments was comparable to the prior ~~year, primarily due to the extinguishment of acquisition-related obligations. Interest income increased $0.1 million due to earnings on short-term investments.~~year.

Foreign currency (gains) losses, net

Foreign currency (gains) losses, net for the three months ended September 30, ~~2018,~~2019, amounted to net ~~gains~~losses of ~~$2.6~~$3.2 million, as compared to ~~$0.3~~$2.6 million in net ~~losses~~gains for the three months ended September 30, ~~2017. Foreign currency net gains in the three months ended September 30, 2018, were primarily due to the movement of the Turkish, Mexican and Brazilian currencies relative to the U.S. dollar.~~2018. Foreign currency gains and losses primarily arose from ~~cash~~intercompany balances and ~~intercompany balances.~~the effects of a currency devaluation in Argentina.

Provision for income taxes

The provision for income taxes was ~~$6.4~~$1.1 million and ~~$3.1~~$6.4 million for the three months ended September 30, ~~2018~~2019 and ~~2017,~~2018, respectively. The effective income tax rate was ~~28.1%~~29.6% and ~~16.1%~~28.1% for the three months ended September 30, ~~2018~~2019 and ~~2017,~~2018, respectively. The provision for income taxes during the three months ended September 30, 2018, included a benefit from the exercise of employee stock options of $0.2 ~~million and $2.7 million for the three months ended September 30, 2018 and 2017, respectively.~~million. The effective income tax rate, without the benefit of the employee stock option exercises, would have been 28.8% ~~and 30.6%~~ for the three months ended September 30, ~~2018 and 2017, respectively. The provision for~~2018.

Net income ~~taxes included a U.S. federal statutory tax rate~~

Net income of ~~21% and 35%~~$2.5 million for the three months ended September 30, ~~2018 and 2017, respectively. The provision for income taxes for the three months ended September 30, 2018, also included a $0.3~~2019, decreased $13.8 million, ~~provision for the U.S. federal Global Intangible Low-taxed Income (GILTI) aspects of the comprehensive U.S. income tax legislation.~~

TABLE OF CONTENTS

by lower income tax expense of $5.3 million. The decline in operating income was driven by an $8.1 million reduction in gross profit, on reduced volumes and unfavorable product mix, and increased SG&A costs of $4.6 million as ~~compared~~we continue to ~~net income~~invest in product development and strategic growth initiatives.

Adjusted EBITDA

Adjusted EBITDA of ~~$15.9~~$19.7 million for the three months ended September 30, ~~2017. Increased operating income of $0.5~~2019, decreased $10.4 million, lower interest expense of $0.3 million and increased foreign exchange gains of $3.0 million resulted in a $3.8 million increase in income before income taxes. The provision for income taxes increased by $3.3 million, primarily dueor 35%, as compared to a reduced benefit from the exercise of employee stock options of $2.5 million and increased taxes related to the higher pre-tax income; the reduced U.S. federal statutory tax rate in the current year partially offset the increases.

~~Adjusted EBITDA~~

~~Adjusted EBITDA of $30.1 million for~~ the three months ended September 30, ~~2018, was even with the three months ended September 30, 2017.~~2018. Animal Health Adjusted EBITDA ~~increased $2.0~~decreased $10.7 million ~~or 6%,~~ due to reduced sales ~~growth~~volumes and ~~increased~~the related gross profit ~~partially offset by~~decline, coupled with increased SG&A costs for ~~investments in organization~~product development and ~~business development.~~strategic growth initiatives. Mineral Nutrition Adjusted EBITDA ~~decreased $1.2~~increased $0.9 million, ~~or 31%, due to the effect of unfavorable product mix and pricing pressures on~~driven by increased gross profit. Performance Products Adjusted EBITDA increased ~~$0.5~~$0.1 million. Corporate expenses increased $0.8 million due to increased ~~gross profit. Corporate expenses increased $1.2 million due to increased business development expenses~~costs of strategic initiatives and ~~higher professional fees.~~public company costs.

Analysis of financial condition, liquidity and capital resources

Net increase (decrease) in cash and cash equivalents was:

	Three Months									Three Months
For the Periods Ended September 30	2018			2017			Change			2019			2018			Change
	(in thousands)									(in thousands)
Cash provided by/(used in):
Operating activities		$	1,280		$	4,803		$	(3,523)		$	(3,570)		$	1,280		$	(4,850)
Investing activities			(16,149)			(16,832)			683			(62,531)			(16,149)			(46,382)
Financing activities			11,734			17,845			(6,111)			63,931			11,734			52,197
Effect of exchange-rate changes on cash and cash equivalents			(173)			198			(371)			(510)			(173)			(337)
Net increase/(decrease) in cash and cash equivalents		$	(3,308)		$	6,014		$	(9,322)		$	(2,680)		$	(3,308)		$	628

Certain amounts may reflect rounding adjustments.

Net cash provided (used) by operating activities was comprised of:

	Three Months									Three Months
For the Periods Ended September 30	2018			2017			Change			2019			2018			Change
	(in thousands)									(in thousands)
EBITDA	��	$	32,179		$	28,706		$	3,473		$	14,707		$	32,179		$	(17,472)
Adjustments
Restructuring costs												425			—			425
Stock-based compensation			565			—			565			565			565			—
Acquisition-related cost of goods sold			—			249			(249)			280			—			280
Acquisition-related accrued compensation			—			437			(437)
Acquisition-related transaction costs			—			400			(400)			462			—			462
Foreign currency (gains) losses, net			(2,635)			325			(2,960)			3,221			(2,635)			5,856
Interest paid			(2,732)			(2,679)			(53)			(3,201)			(2,732)			(469)
Income taxes paid			(5,817)			(4,039)			(1,778)			(4,657)			(5,817)			1,160
Changes in operating assets and liabilities and other items			(20,280)			(18,196)			(2,084)			(14,910)			(20,280)			4,908
Cash used for acquisition-related transaction costs			—			(400)			400			(462)			—			(462)
Net cash provided (used) by operating activities		$	1,280		$	4,803		$	(3,523)		$	(3,570)		$	1,280		$	(4,850)

Certain amounts may reflect rounding adjustments.

2427

TABLE OF CONTENTS

Operating activities

Net cash ~~provided~~used by operating activities was ~~$1.3~~$3.6 million for the three months ended September 30, ~~2018.~~2019. Cash provided by net income and non-cash items of $12.5 million, including depreciation and amortization, ~~and foreign exchange gains,~~ was ~~largely~~ offset by $16.1 million of cash used in the ordinary course of business for changes in operating assets and liabilities and other items. Accounts payable used $11.8 million of cash due to the timing of payments for inventory purchases. Increased inventories used ~~$9.5~~$9.1 million of cash due to the timing of sales, purchases and production. ~~Accounts payable provided $2.8 million of cash, primarily related to the timing of inventory purchases.~~ Accrued expenses and other liabilities used ~~$9.2~~$7.4 million of cash primarily due to ~~annual incentive compensation~~timing of payments for professional fees, employee related costs and customer commissions and rebates. Accounts receivable provided $14.1 million of cash due to the ~~previous fiscal year.~~timing of sales and collections in international regions.

Investing activities

Net cash used in investing activities was ~~$16.1~~$62.5 million for the three months ended September 30, ~~2018.~~2019. Cash used for ~~business acquisitions~~the Osprey acquisition was ~~$9.8~~$54.6 million. Capital expenditures were ~~$6.0~~$7.7 million as we continued to invest in our existing asset base and for capacity expansion and productivity improvements. ~~Other investing activities used $0.3 million of cash.~~

Financing activities

Net cash provided by financing activities was ~~$11.7~~$63.9 million for the three months ended September 30, ~~2018.~~2019. Net borrowings on our Revolver provided ~~$15.0 million. We partially financed an acquisition of a business through~~$72.0 million, primarily to fund the ~~issuance of a $3.8 million short-term note payable. We received $0.2 million from~~cash paid for the ~~issuance of common shares related to the exercise of stock options.~~Osprey acquisition. We paid ~~$4.0~~$4.9 million in dividends to holders of our Class A and Class B common stock. We paid $3.2 million in scheduled debt and other requirements.

Liquidity and capital resources

We believe our cash on hand, our operating cash flows and our financing arrangements, including the availability of borrowings under the Revolver and foreign credit lines, will be sufficient to support our ~~future~~ongoing cash needs. Our operating plan projects adequate liquidity throughout the year. However, we can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the Credit Facilities and foreign credit lines based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that a challenging economic environment or an economic downturn would not ~~impact~~affect our liquidity or our ability to obtain future financing. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources follow:

As of	September 30, 2018			June 30, 2018			Change			September 30, 2019			June 30, 2019
	(in thousands, except ratios)									(in thousands, except ratios)
Cash and cash equivalents and short-term investments		$	75,860		$	79,168		$	(3,308)		$	78,893		$	81,573
Working capital			227,782			205,651			22,431			248,730			242,902
Ratio of current assets to current liabilities			2.96:1			2.57:1						2.94:1			2.71:1

We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding ~~the~~ current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

At September 30, ~~2018,~~2019, we had ~~$85.0~~$168.0 million in outstanding borrowings under the Revolver. We had outstanding letters of credit and other commitments of ~~$4.2~~$3.0 million, leaving ~~$160.8~~$79.0 million available for borrowings and letters of credit.

TABLE OF CONTENTS

November ~~28, 2018,~~27, 2019, payable on December ~~19, 2018. The December 2018 quarterly dividend is a 20% increase over the $0.10 per share quarterly dividend declared and paid previously. We expect~~18, 2019. Our future ability to pay ~~future quarterly~~ dividends will depend upon our results of ~~$0.12 per share on~~operations, financial condition, capital requirements, our ~~Class A~~ability to obtain funds from our subsidiaries and ~~Class B common stock, representing approximately $19.4 million annually, subject to approval from the~~other factors that our Board of ~~Directors.~~Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.

AtAs of September 30, ~~2018,~~2019, our cash and cash equivalents and short-term investments included ~~$74.3~~$76.3 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.

Contractual obligations

As of September 30, ~~2018,~~2019, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report on Form 10-K for the year ended June 30, ~~2018.~~2019.

Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

~~General description of non-GAAP financial measures~~

Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to portray the results of our operations prior to considering certain income statement elements. We have defined EBITDA as net income (loss) plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We have defined Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income.

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

•

senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;

•

our annual budgets are prepared on an Adjusted EBITDA basis; and

•

other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. We present Adjusted EBITDA ~~is presented~~ to permit investors to more fully understand how management assesses performance.

TABLE OF CONTENTS

Certain significant items

Adjusted EBITDA is calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis.

We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives, including employee separation costs, to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

New accounting standards

We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), effective July 1, 2019.

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”

Critical Accounting Policies

Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, assessment of the incremental borrowing rates and reasonably certain renewal periods associated with our lease agreements, legal and environmental matters and actuarial assumptions related to our pension plans. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in the Annual Report. As of September 30, ~~2018,~~2019, there have been no material changes to any of the critical accounting policies contained therein, ~~except for~~other than those related to the adoption of the new lease standard, ~~related to revenue recognition.~~ASU 2016-02, Leases (Topic 842). See “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards” for the changes made to our ~~revenue recognition policy, following the adoption of Financial Accounting Standards Board Accounting Standards Update 2014-09,~~ ~~Revenue from Contracts with Customers (Topic 606).~~lease accounting policy.

Forward-Looking Statements

This ~~report~~Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial ~~results, our plans and~~

2730

TABLE OF CONTENTS

results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

•

perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;

•

restrictions on the use of antibacterials in food-producing animals may become more prevalent;

•

a material portion of our sales and gross profits are generated by antibacterials and other related products;

•

competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;

•

outbreaks of animal diseases could significantly reduce demand for our products;

•

our business may be negatively affected by weather conditions and the availability of natural resources;

•

the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;

•

our ability to control costs and expenses;

•

any unforeseen material loss or casualty;

•

exposure relating to rising costs and reduced customer income;

•

competition deriving from advances in veterinary medical practices and animal health technologies;

•

unanticipated safety or efficacy concerns;

•

our dependence on suppliers having current regulatory approvals;

•

our raw materials are subject to price fluctuations and their availability can be limited;

•

natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;

•

terrorist attacks, particularly attacks on or within markets in which we operate;

•

our ability to successfully implement our strategic initiatives;

•

our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;

•

adverse U.S. and international economic market conditions, including currency fluctuations;

•

failure of our product approval, R&D, acquisition and licensing efforts to generate new products;

•

the risks of product liability claims, legal proceedings and general litigation expenses;

•

the impact of current and future laws and regulatory changes;

•

modification of foreign trade policy may harm our food animal product customers

•

our dependence on our Israeli and Brazilian operations;

•

our substantial level of indebtedness and related debt-service obligations;

•

restrictions imposed by covenants in our debt agreements;

2831

TABLE OF CONTENTS

•

the risk of work stoppages; and

•

other factors as described in “Risk Factors” in Item 1A. of ~~this~~our Annual Report on Form 10-K.

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We ~~also utilize, on a limited basis, certain commodity derivatives, primarily on copper used in manufacturing processes, to hedge the cost of anticipated purchase or supply requirements. We~~ do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that completely eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

For financial market risks related to changes in interest rates and foreign currency exchange rates, ~~and commodity prices,~~ reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. There were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)). Based upon that evaluation as of September 30, ~~2018,~~2019, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were not effective because of material weaknesses in our internal control over financial reporting, as described in Management’s Report on Internal Control over Financial Reporting in “Item 9A. Controls and Procedures” in the Annual Report on Form 10-K for the year ended June 30, ~~2018.~~2019.

Material Weakness Remediation Efforts

We continue to make further progress in implementing a broad range of changes to ~~strengthen~~ our internal control over financial reporting ~~and~~ to remediate the material weaknesses ~~that existed as of June 30, 2018.~~described in this item. Our actions to address the material weaknesses have included the design and implementation of

TABLE OF CONTENTS

reported, appropriately authorized and approved. Also, our efforts to ensure maintenance of the appropriate level of segregation of duties includes restricting access to key financial systems and records to appropriate users. We ~~have decreased~~continue to make improvements by reducing the ~~level~~number of segregation of duties conflicts and continue to ~~determine~~evaluate the extent it is necessary to limit access and modify responsibilities of certain personnel, as well as designing and implementing additional user access controls and compensating controls. We have completed a gap analysis of our key controls. In completing this analysis, we identified areas where new controls were needed and enhancements to existing controls, policies and procedures need to be made. Through this analysis, we have developed a workplan for remediation of our material weaknesses. The remediation plan includes enhancing and supplementing the finance team by increasing the number of roles, reassigning responsibilities, and adding additional resources with an appropriate level of knowledge and experience in internal control over financial reporting commensurate with our financial reporting requirements. We will continue to build on the progress we have made in our remediation plan. We cannot determine when our remediation plan will be fully completed, and we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

Changes in Internal Control over Financial Reporting

There have been no changes in internal control over financial reporting during the three months ended September 30, ~~2018~~2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3033

	Page
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)		3
Consolidated Statements of Operations		3
Consolidated Statements of Comprehensive Income		4
Consolidated Balance Sheets		5
Consolidated Statements of Cash Flows		6
Consolidated Statements of Changes in Stockholders’ Equity		7
Notes to Consolidated Financial Statements		78
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		2022
Item 3. Quantitative and Qualitative Disclosures About Market Risk		2932
Item 4. Controls and Procedures		2932
PART II—OTHER INFORMATION
Item 1. Legal Proceedings		3134
Item 1A. Risk Factors		3134
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		3134
Item 3. Defaults Upon Senior Securities		3134
Item 4. Mine Safety Disclosures		3134
Item 5. Other Information		3134
~~Item 6.~~ SIGNATURES ~~Exhibits~~		32
~~SIGNATURES~~		3336

As of July 1, 2018	Effect of Adoption			Post-adoption
Other current assets		$	2,100		$	24,481
Other assets			2,325			49,109
Accrued expenses and other current liabilities			343			71,487
Other liabilities			2,837			46,539
Retained earnings		$	1,245		$	132,805

As of September 30, 2018	Effect of adoption			As reported
ASSETS
Other current assets		$	56		$	23,324
Other assets			56			48,660
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accrued expenses and other current liabilities			(80)			54,281
Other liabilities			26			45,937
Retained earnings		$	166		$	145,082

	Three Months
For the Period Ended September 30, 2018	Effect of adoption			As reported
Net sales		$	198		$	200,153
Provision for income taxes			32			6,391
Net income		$	166		$	16,314

As of	September 30, 2018						June 30, 2018
	Level 1			Level 2			Level 1			Level 2
Short-term investments		$	50,000		$	—		$	50,000		$	—
Derivatives asset (liability)		$	—		$	(60)		$	—		$	71
Interest rate swap		$	—		$	5,728		$	—		$	5,078

				Exhibit ~~10.18* First Amendment, dated July 31, 2018 to the Intellectual Property~~2.1 Asset Purchase Agreement ~~drafted as of January 20, 2015,~~ by and among ~~MJ Biologics, Inc. and~~ Phibro Animal Health Corporation, as Purchaser, Osprey Biotechnics, Inc., as Company and together with Lauren Danielson and Vincent Scuilla, as Selling Parties dated as of August 1, 2019 (Filing excludes certain schedules (or similar attachments) pursuant to Item 601(a)(5) of Regulation S-K, which the registrant agrees to furnish supplementally to the SEC upon request by the SEC).
				Exhibit 31.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
				Exhibit 31.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
				Exhibit 32.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
				Exhibit 32.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
				Exhibit 101.INS** XBRL Instance Document
				Exhibit 101.SCH** XBRL Taxonomy Extension Schema Document
				Exhibit 101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document
				Exhibit 101.DEF** XBRL Taxonomy Extension Definition Linkbase Document
				Exhibit 101.LAB** XBRL Taxonomy Extension Label Linkbase Document
				Exhibit 101.PRE** XBRL Taxonomy Extension Presentation Linkbase Document

	Phibro Animal Health Corporation
November ~~6, 2018~~4, 2019	By:	/s/ Jack C. Bendheim Jack C. Bendheim Chairman, President and Chief Executive Officer
November ~~6, 2018~~4, 2019	By:	/s/ Richard G. Johnson Richard G. Johnson Chief Financial Officer